Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2013 Jun 29:Suppl 3:006.
doi: 10.4172/2155-6113.S3-006.

Hepatitis B Co-Infection is Associated with Poorer Survival of HIV-Infected Patients on Highly Active Antiretroviral Therapy in West Africa

Nimzing G Ladep  1 , Oche O Agbaji  2 , Patricia A Agaba  3 , Auwal Muazu  2 , Placid Ugoagwu  2 , Godwin Imade  2 , Graham S Cooke  1 , Livia Vivas  4 , Sheena Mc Cormack  4 , Simon D Taylor-Robinson  1 , John Idoko  5 , Phyllis Kanki  6
Affiliations

Hepatitis B Co-Infection is Associated with Poorer Survival of HIV-Infected Patients on Highly Active Antiretroviral Therapy in West Africa

Nimzing G Ladep et al. J AIDS Clin Res. .

Abstract

Background: Hepatitis B has been reported to be high in HIV-infected African populations. However, the impact of this co-infection on the survival of HIV-infected Africans on long-term highly active antiretroviral therapy (HAART) remains poorly characterised. We investigated the impact of HBV/HIV co-infection on survival of HIV infected patients undergoing antiretroviral therapy in a West African population.

Methods: This was a clinic-based cohort study of HIV-infected adults enrolled in Nigeria, West Africa. Study subjects (9,758) were screened for hepatitis B and hepatitis C at HAART initiation. Kaplan-Meier survival and Cox proportional hazards models were used to estimate probability of survival and to identify predictors of mortality respectively, based on hepatitis B surface antigen status. All patients had signed an informed written consent before enrolment into the study; and we additionally obtained permission for secondary use of data from the Harvard institutional review board.

Results: Patients were followed up for a median of 41 months (interquartile range: 30-62 months) during which, 181 (1.9%) patients died. Most of the deaths; 143 (79.0%) occurred prior to availability of Tenofovir. Among those that were on antiretroviral therapy, hepatitis B co-infected patients experienced a significantly lower survival than HIV mono-infected patients at 74 months of follow up (94% vs. 97%; p=0.0097). Generally, hepatitis B co-infection: HBsAg-positive/HIV-positive (Hazards Rate [HR]; 1.5: 95% CI 1.09-2.11), co-morbid tuberculosis (HR; 2.2: 95% CI 1.57-2.96) and male gender (HR; 1.5: 95% CI 1.08-2.00) were significantly predictive of mortality. Categorising the patients based on use of Tenofovir, HBV infection failed to become a predictor of mortality among those on Tenofovir-containing HAART.

Conclusions: HBsAg-positive status was associated with reduced survival and was an independent predictor of mortality in this African HIV cohort on HAART. However, Tenofovir annulled the impact of HBV on mortality of HIV patients in the present study cohort.

Keywords: Africa; CD4; HAART; HIV; Hepatitis B surface antigen; Mortality; Survival.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Profile of study cohort, AIDS Prevention Initiative in Nigeria, Jos University Teaching Hospital, Nigeria, 2004–2010.
Figure 2
Figure 2
Kaplan-Meier survival curves according to hepatitis co-infection status for: both sexes; and men; APIN 2004–2010; HBV: Hepatitis B virus; HCV: hepatitis C virus.
See this image and copyright information in PMC

References

    1. de Martel C, Ferlay J, Franceschi S, Vignat J, Bray F, et al. Global burden of cancers attributable to infections in 2008: a review and synthetic analysis. Lancet Oncol. 2012;13:607–615. - PubMed
    1. Ott JJ, Stevens GA, Groeger J, Wiersma ST. Global epidemiology of hepatitis B virus infection: new estimates of age-specific HBsAg seroprevalence and endemicity. Vaccine. 2012;30:2212–2219. - PubMed
    1. Forbi JC, Gabadi S, Alabi R, Iperepolu HO, Pam CR, et al. The role of triple infection with hepatitis B virus, hepatitis C virus, and human immunodeficiency virus (HIV) type-1 on CD4+ lymphocyte levels in the highly HIV infected population of North-Central Nigeria. Mem Inst Oswaldo Cruz. 2007;102:535–537. - PubMed
    1. Mayaphi SH, Roussow TM, Masemola DP, Olorunju SA, Mphahlele MJ, et al. HBV/HIV co-infection: the dynamics of HBV in South African patients with AIDS. S Afr Med J. 2012;102:157–162. - PubMed
    1. Zachariah R, Fitzgerald M, Massaquoi M, Pasulani O, Arnould L, et al. Risk factors for high early mortality in patients on antiretroviral treatment in a rural district of Malawi. AIDS. 2006;20:2355–2360. - PubMed